TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Mar 31, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 7, 2025
TEVA$42.61+2.0%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
| ITEM 5. | OTHER INFORMATION |
|---|
Director and Officer Rule
10b5-1
Trading Arrangements
During the three months ended March 31, 2025, the following officer adopted a
“non-Rule
10b5-1
trading arrangement” (as such term is defined in Item 408 of Regulation
S-K).
| Name and Title | Date | Action | Expiration Date | Maximum SharesSubject to Plan (1) |
|---|---|---|---|---|
| Matthew Shields, Executive Vice President, Teva Global Operations | March 13, 2025 | Adopted | June 5, 2025 | 16,195 |
| (1) | The plan includes shares to be sold solely to cover tax withholding obligations. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.